Development and clinical validation of an ERA-CRISPR/Cas12a assay for the rapid detection of 14 high-risk HPV types
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.03036-25 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Zhijie Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, CRISPR-Cas Systems, Molecular Diagnostic Techniques, Nucleic Acid Amplification Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tongji Hospital.
Abstract (Originalsprache)
Persistent infection with high-risk human papillomavirus (HR-HPV) is the leading cause of cervical cancer, highlighting the critical need for early detection to improve prevention. Although real-time quantitative polymerase chain reaction (RT-qPCR) remains the gold standard for HR-HPV detection, its dependence on sophisticated equipment, complex procedures, and trained personnel limits accessibility. Here, we developed a simplified assay for 14 HR-HPV types by integrating direct lysis, enzyme-mediated isothermal rapid amplification (ERA), and CRISPR-Cas12a-mediated cleavage into a streamlined workflow that requires only a basic isothermal heating device. The optimized system achieved a sensitivity of 50 copies per reaction with no cross-reactivity, while a refined lysis buffer containing 20% Chelex-100 minimized inhibition from vaginal swab samples, thereby enhancing detection performance. Validation with 152 clinical samples demonstrated 97.62% sensitivity and 100% specificity, confirming the reliability of the method. This user-friendly and cost-effective assay requires minimal equipment, enabling rapid and field-deployable HR-HPV detection, and offers a practical alternative to conventional laboratory-based approaches, particularly in resource-limited settings. IMPORTANCE High-risk human papillomavirus (HR-HPV) is the principal etiological agent of cervical cancer, and early detection remains central to effective disease prevention. Current PCR-based assays, however, rely on specialized laboratories and trained personnel, limiting their deployment in many settings. Here, we report a streamlined CRISPR-Cas12a assay that integrates direct sample lysis, ERA, and CRISPR-based detection into a single workflow operable with only a simple heating device to determine the presence of 14 HR-HPV types. The assay achieves high analytical sensitivity, strong specificity, and robust clinical performance while maintaining low cost and ease of use. This platform enables rapid HR-HPV detection and scalable screening, particularly in resource-constrained environments, with the potential to facilitate earlier intervention and reduce cervical cancer incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and…
- Wuhan Kandwise Biotechnology, Inc. Wuhan, Hubei, China.
ORCID-Profile: Zhijie Wang, Xiaoyuan Huang, Liang He
Förderung
- National Natural Science Foundation of China
- Tongji Hospital
Zitieren
APA
Wang, Z., Hu, T., Liu, W., Zhou, H., Lv, X., Li, H., Li, X., Huang, X., & He, L. (2026). Development and clinical validation of an ERA-CRISPR/Cas12a assay for the rapid detection of 14 high-risk HPV types. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03036-25
Vancouver
Wang Z, Hu T, Liu W, Zhou H, Lv X, Li H, et al. Development and clinical validation of an ERA-CRISPR/Cas12a assay for the rapid detection of 14 high-risk HPV types. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03036-25
BibTeX
@article{Wang2026,
author = {Wang, Zhijie and Hu, Ting and Liu, Wanxin and Zhou, Hu and Lv, Xinyi and Li, Hui and Li, Xuemeng and Huang, Xiaoyuan and He, Liang},
title = {Development and clinical validation of an ERA-CRISPR/Cas12a assay for the rapid detection of 14 high-risk HPV types},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.03036-25}
}
EUVIMED